Study of a new medicine for heart failure with preserved pumping function
Part of Heart & circulation clinical trials.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 84 years old.
- You weigh at least 45 kg (about 99 pounds) and your body mass index (BMI) is less than 40.
- You have been diagnosed with heart failure and have mild to moderate symptoms (NYHA class II or III).
- Your heart's pumping ability is preserved (ejection fraction 50% or higher).
- If you take heart failure medications, you have been on stable doses.
- If you use a GLP-1 agonist (like Ozempic or Wegovy), you don't plan to change the dose during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a type of heart failure where the heart pumps normally but is too stiff to fill properly. It aims to better understand and classify this condition, which may help guide future treatments.
This study looks at how the heart muscle works in people with a type of heart failure where the heart pumps normally but doesn't fill properly. It aims to understand the cause better, which could lead to new treatments.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
This study tests an experimental medicine, CDR132L, to see if it can improve heart structure and function in people with a type of heart failure where the heart muscle is thickened. If you have heart failure with normal pumping function and thickened heart walls, this trial may offer access to a new potential treatment.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.